LGVN · Insider Trading
Longeveron Inc. Common Stock
Every open-market purchase and sale reported by LGVN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Nataliya Agafonova | Chief Medical Officer | F | −2,913 | −$7.54K |
| 2026-10-05 | Devin Blass | CTO & SVP of CMC | F | −2,520 | −$6.53K |
| 2026-10-05 | Stephen H Willard | Chief Executive Officer | F | −1,987 | −$5.15K |
| 2026-10-05 | Paul T Lehr | General Counsel, Secretary | F | −2,253 | −$5.84K |
| 2026-10-05 | Nirav S. Jhaveri | Chief Financial Officer | F | −742 | −$1.92K |
| 2026-08-25 | Nirav S. Jhaveri | Chief Financial Officer | A | +300,000 | — |
| 2026-08-21 | Deborah Ascheim | Director | A | +36,000 | — |
| 2026-08-21 | Devin Blass | CTO & SVP of CMC | A | +286,000 | — |
| 2026-08-21 | George A. Paletta Jr. | Director | A | +36,000 | — |
| 2026-08-21 | Rock Soffer | Director | A | +36,000 | — |
| 2026-08-21 | Roger Joseph Hajjar | Director | A | +36,000 | — |
| 2026-08-21 | Arjun JJ Desai | Director | A | +36,000 | — |
| 2026-08-21 | Paul T Lehr | General Counsel, Secretary | A | +286,000 | — |
| 2026-08-21 | Nataliya Agafonova | Chief Medical Officer | A | +286,000 | — |
| 2026-08-21 | Leah Rush Cann | Director | A | +36,000 | — |
| 2026-08-21 | Joshua Hare | Chief Scientific Officer | A | +286,000 | — |
| 2026-08-21 | Ursula Ungaro | Director | A | +36,000 | — |
| 2026-07-08 | Joshua Hare | Chief Scientific Officer | A | +600,000 | — |
| 2026-07-06 | Stephen H Willard | Chief Executive Officer | F | −18,046 | −$13.16K |
| 2026-07-06 | Paul T Lehr | General Counsel, Secretary | F | −13,143 | −$9.58K |
| 2026-07-06 | Lisa Locklear | Chief Financial Officer | F | −22,505 | −$16.41K |
| 2026-07-06 | Nataliya Agafonova | Chief Medical Officer | F | −22,505 | −$16.41K |
| 2026-07-06 | Devin Blass | CTO & SVP of CMC | F | −15,808 | −$11.53K |
| 2026-05-05 | Nataliya Agafonova | Chief Medical Officer | A | +250,000 | — |
| 2026-05-05 | Stephen H Willard | Chief Executive Officer | A | +500,000 | — |
| 2026-05-05 | Paul T Lehr | General Counsel, Secretary | A | +250,000 | — |
| 2026-05-05 | Lisa Locklear | Chief Financial Officer | A | +250,000 | — |
| 2026-05-05 | Devin Blass | CTO & SVP of CMC | A | +250,000 | — |
| 2026-04-03 | Lisa Locklear | Chief Financial Officer | F | −13,145 | −$14.72K |
| 2026-04-03 | Devin Blass | CTO & SVP of CMC | F | −8,633 | −$9.67K |
| 2026-04-03 | Nataliya Agafonova | Chief Medical Officer | F | −13,145 | −$14.72K |
| 2026-04-03 | Stephen H Willard | Chief Executive Officer | F | −4,740 | −$5.31K |
| 2026-04-03 | Paul T Lehr | General Counsel, Secretary | F | −5,611 | −$6.28K |
| 2026-03-13 | Stephen H Willard | Chief Executive Officer | MIXED | +294,467 | −$57.52K |
| 2026-01-06 | James Nathaniel Powell | Chief Executive Officer | F | −2,464 | −$1.46K |
| 2026-01-06 | Devin Blass | CTO & SVP of CMC | F | −10,700 | −$6.35K |
| 2026-01-06 | Nataliya Agafonova | Chief Medical Officer | F | −10,250 | −$6.08K |
| 2026-01-06 | Lisa Locklear | Chief Financial Officer | F | −10,250 | −$6.08K |
| 2026-01-06 | Paul T Lehr | General Counsel, Secretary | F | −6,952 | −$4.12K |
| 2025-10-27 | George A. Paletta Jr. | Director | A | +34,000 | — |
| 2025-10-03 | Paul T Lehr | General Counsel, Secretary | F | −4,944 | −$3.67K |
| 2025-10-03 | Devin Blass | CTO & SVP of CMC | F | −7,609 | −$5.65K |
| 2025-10-03 | Lisa Locklear | Chief Financial Officer | F | −11,883 | −$8.82K |
| 2025-10-03 | James Nathaniel Powell | Chief Executive Officer | F | −2,389 | −$1.77K |
| 2025-10-03 | Nataliya Agafonova | Chief Medical Officer | F | −11,883 | −$8.82K |
| 2025-10-01 | James Nathaniel Powell | Chief Executive Officer | A | +50,000 | — |
| 2025-08-13 | Khoso Baluch | Director | Buy | +11,766 | — |
| 2025-08-13 | Lisa Locklear | Chief Financial Officer | Buy | +11,766 | — |
| 2025-07-17 | Richard N Kender | Director | A | +17,000 | — |
| 2025-07-17 | Ursula Ungaro | Director | A | +17,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joshua Hare | Chief Scientific Officer | 161,315 | $258.91K |
| Paul T Lehr | General Counsel, Secretary | 83,889 | $134.64K |
| Stephen H Willard | Chief Executive Officer | 74,916 | $120.24K |
| Nataliya Agafonova | Chief Medical Officer | 68,778 | $110.39K |
| Devin Blass | CTO & SVP of CMC | 68,653 | $110.19K |
| Lisa Locklear | Chief Financial Officer | 44,318 | $71.13K |
| Mohamed Wa'el Ahmed Hashad | Chief Executive Officer | 42,090 | $67.55K |
| Nirav S. Jhaveri | Chief Financial Officer | 29,258 | $46.96K |
| Rock Soffer | Director | 26,203 | $42.06K |
| James Nathaniel Powell | Chief Executive Officer | 12,559 | $20.16K |
| Ursula Ungaro | Director | 7,700 | $12.36K |
| George A. Paletta Jr. | Director | 7,000 | $11.23K |
| Roger Joseph Hajjar | Director | 6,900 | $11.07K |
| Khoso Baluch | Director | 5,252 | $8.43K |
| Arjun JJ Desai | Director | 3,600 | $5.78K |
| Deborah Ascheim | Director | 3,600 | $5.78K |
| Leah Rush Cann | Director | 3,600 | $5.78K |
| Neha J. Motwani | Director | 3,300 | $5.30K |
| Richard N Kender | Director | 3,300 | $5.30K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LGVN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.